Clinical Trials on Biological Availability in Japan

Total 62 results

Ferring Pharmaceuticals

Completed

Trial Investigating the Long Term Safety and Tolerability of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Nocturia

Japan
Ferring Pharmaceuticals

Completed

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Male Subjects

Nocturia

Japan
Ferring Pharmaceuticals

Completed

Trial of Desmopressin Orally Disintegrating Tablets (ODT) for Nocturia Due to Nocturnal Polyuria in Japanese Female Subjects

Nocturia

Japan
Sanofi

Completed

Dose Ranging Study of Alfuzosin in Patients With Lower Urinary Tract Symptoms Related to Benign Prostatic Hyperplasia

Benign Prostatic Hyperplasia

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Nocturia Due to Nocturnal Polyuria

Japan
Astellas Pharma Inc

Completed

A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients

Urinary Bladder, Overactive

Japan
Ono Pharmaceutical Co. Ltd
Kyorin Pharmaceutical Co.,Ltd

Completed

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Overactive Bladder

Japan
Ferring Pharmaceuticals

Completed

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Men (NOC)

Nocturia

Japan
Ferring Pharmaceuticals

Completed

Comparative Trial to Investigate the Efficacy and Safety of Desmopressin for the Treatment of Nocturia in Adult Women (NOC)

Nocturia

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Trial of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.

Overactive Bladder | Detrusor Underactivity

Japan
Astellas Pharma Inc

Completed

A Study of YM178 in Patients With Symptomatic Overactive Bladder

Urinary Bladder, Overactive

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder

Urinary Bladder, Overactive

Japan
Ferring Pharmaceuticals

Completed

Specified Drug Use-results Survey (Long-term Use) on MINIRINMELT® OD Tablet (Nocturia) (NOC01)

Nocturia Due to Nocturnal Polyuria

Japan
Translational Research Center for Medical Innovation...
Shinshu University Hospital

Completed

Female Patients With Signs of uRgE and Stress Urinary Incontinence Study of Propiverine Hydrochloride (FRESH)

Urinary Incontinence

Japan
Astellas Pharma Inc

Completed

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

Overactive Bladder

Japan
Shiga University

Unknown

Rationale and Design for Shiga Microalbuminuria Reduction Trial

Hypertension | Diabetes Mellitus | Albuminuria

Japan
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Bayer

Completed

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

Post Marketing Survey of Vesicare in Japan (SET-Q)

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.

Overactive Bladder (OAB)

Japan
Astellas Pharma Inc

Completed

Long-Term Specified Drug Use-results Survey of Betanis Tablets

Overactive Bladder

Japan
Astellas Pharma Inc

Completed

Drug Use-Results Survey of Betanis Tablets in Japan

Overactive Bladder

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder

Japan
Kissei Pharmaceutical Co., Ltd.

Withdrawn

Long-term Safety and Efficacy of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder

Japan
Daiichi Sankyo Co., Ltd.

Completed

Study of CS-3150 in Hypertensive Patients With Type 2 Diabetes and Albuminuria

Hypertension

Japan
Daiichi Sankyo Co., Ltd.

Completed

ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy Trial

Type 2 Diabetes Mellitus | Diabetic Nephropathy | Proteinuria

Japan, China
Nagoya University

Completed

Clinical Trial of Autologous Adipose Derived Regenerative Cells for the Treatment of Male Stress Urinary Incontinence (ADRESU)

Urinary Incontinence , Stress

Japan
Astellas Pharma Inc

Completed

Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Overactive Bladder | Cardiovascular Disease

Japan
GlaxoSmithKline

Completed

Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity

Urinary Bladder, Overactive

Japan
Astellas Pharma Inc

Completed

Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia

Overactive Bladder | Benign Prostatic Hyperplasia | Benign Prostatic Hypertrophy

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Study of KUC-7483 in Patients With Overactive Bladder

Overactive Bladder (OAB)

Japan
Ferring Pharmaceuticals

Completed

Comparative Trial to Investigate the Dose-Response of 4 Different Dose Levels of Minirin Melt and Placebo (NOC)

Nocturia

Japan
Astellas Pharma Inc
Astellas Pharma Singapore Pte. Ltd.

Completed

A Phase 4 Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Male Subjects With Overactive Bladder (OAB) Symptoms, While Taking the Alpha Blocker for Benign Prostatic Hypertrophy (BPH)

Overactive Bladder

Japan, Korea, Republic of
Ferring Pharmaceuticals

Completed

Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis (PNE)

Nocturnal Enuresis

Japan
GlaxoSmithKline

Completed

Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder

Urinary Bladder, Overactive

Japan
Novartis Pharmaceuticals

Completed

Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria

Paroxysmal Nocturnal Hemoglobinuria PNH

Lithuania, Japan, Czechia
Kirby Institute

Completed

MARCH Renal Substudy (MARCHrenal)

Proteinuria | HIV

Canada, Australia, Germany, Argentina, Japan, Thailand, United Kingdom, Mexico
Pfizer

Completed

Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivity.

Urinary Bladder, Neurogenic

Japan
AbbVie (prior sponsor, Abbott)

Completed

Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan

Diabetic Nephropathy | Chronic Kidney Disease

Japan
Pfizer

Completed

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

Overactive Bladder

Japan
Astellas Pharma Europe B.V.

Completed

A Study of ASP8302 in Participants With Underactive Bladder

Underactive Bladder

Japan, Poland, Germany, Netherlands, Slovakia, United Kingdom
Ono Pharmaceutical Co. Ltd

Completed

Study of ONO-8577 in Patients With Overactive Bladder

Overactive Bladder

Japan
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria (COMPOSER)

Paroxysmal Hemoglobinuria, Nocturnal

France, Korea, Republic of, Italy, Japan, Germany, Hungary, Netherlands
Regeneron Pharmaceuticals

Recruiting

A Study to Examine the Long-term Safety, Tolerability, and Effectiveness of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (ACCESS-EXT)

Paroxysmal Nocturnal Hemoglobinuria

Taiwan, Korea, Republic of, Turkey, Spain, Thailand, Singapore, Japan, Canada, Malaysia, Poland, Italy
Pfizer

Completed

Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.

Overactive Bladder

Korea, Republic of, Taiwan, Hong Kong, Japan
Alexion

Completed

ALXN1210 Versus Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United States, Korea, Republic of, Canada, France, Germany, Spain, United Kingdom, Japan, Australia, Italy, Netherlands
Apellis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

United States, France, Russian Federation, Korea, Republic of, Canada, Germany, Australia, Japan, Spain, Belgium, United Kingdom

3

Subscribe